Search

Displaying results 2411 - 2420 of 9314 in total
  1. Drug

    Dengue virus serotype 3

    go.drugbank.com/drugs/DB22666
    Approved

    Dengue virus serotype 3 is a serotype of _Orthoflavivirus denguei_ known to cause dengue fever. … [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]

  2. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    the first attack compared to patients receiving placebo [FDA Label, A31579]. … Asthma is a chronic respiratory disease that causes inflammation in the lungs with asthma attacks that lead to severe breathing difficulties.

  3. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    [L64068,L64069] It is the first orexin receptor agonist approved by the FDA and the first medicine to treat NT1 by targeting its underlying cause rather than individual symptoms. … [L64069] The FDA approved oveporexton on August 5, 2026 for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults.

  4. Drug

    Valrubicin

    go.drugbank.com/drugs/DB00385
    Approved

    It is a semisynthetic analog of the [doxorubicin], which is an anthracycline drug. Used in the treatment of the bladder cancer, valrubicin is administered by direct infusion into the bladder. … Valrubicin (N-trifluoroacetyladriamycin-14-valerate) is a chemotherapy drug commonly marketed under the trade name VALSTAR.

  5. Drug

    Prezatide

    go.drugbank.com/drugs/DB11296
    Approved

    Prezatide is used in cosmetic products for the skin and hair. … It is known to aid wound healing and its potential applications in chronic obstructive pulmonary disease and metastatic colon cancer are currently being investigated.

  6. Drug

    Berotralstat

    go.drugbank.com/drugs/DB15982
    ApprovedInvestigational

    [A225106] Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older. … [L26661] It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE.

  7. Drug

    Tolrestat

    go.drugbank.com/drugs/DB02383
    ApprovedWithdrawn

    It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death. … While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval.

  8. Drug

    Ozenoxacin

    go.drugbank.com/drugs/DB12924
    Approved

    To date, ozenoxacin has been used in trials studying the treatment of impetigo. As of December 11, 2017 the FDA approved Ferrer Internacional S.A.' … that has demonstrated safe and effective therapy in both the adult and pediatric population.

  9. Drug

    Pentoxifylline

    go.drugbank.com/drugs/DB00806
    ApprovedInvestigational

    [A226410, A226415, A226455] More recently, PTX has been suggested as a possible treatment for COVID-19-induced pulmonary complications due to its ability to regulate the production of inflammatory cytokines … [A226608] Pentoxifylline has been marketed in Europe since 1972; PTX extended-release tablets sold under the trade name TRENTAL by US Pharm Holdings were first approved by the FDA on Aug 30, 1984, but

    International brands: Bo Shu Te, Ao Le NiProducts: PENTOXIFILINA TABLETAS DE LIBERACIÓN PROLONGADA X 400MG, PENTOXIL TABLETAS DE LIBERACION PROLONGADA 400 MG
  10. Drug

    Tarlatamab

    go.drugbank.com/drugs/DB17256
    ApprovedInvestigational

    T-cell engager to receive marketing approval. … Tarlatamab is a first-in-class T-cell engager used to treat extensive-stage small cell lung cancer.